alexa
Reach Us +44-1647-403003
Predictive And Prognostic Multi-gene Breast Cancer Assays Used In The Clinical Practice In The United States: Analysis Of The National Cancer Data Base | 52977
ISSN: 1948-5956

Journal of Cancer Science & Therapy
Open Access

Like us on:

OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations
700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)
All submissions of the EM system will be redirected to Online Manuscript Submission System. Authors are requested to submit articles directly to Online Manuscript Submission System of respective journal.

Predictive and prognostic multi-gene breast cancer assays used in the clinical practice in the United States: Analysis of the national cancer data base

2nd World Congress on Breast Cancer

Amila Orucevic

University of Tennessee Medical Center, USA

ScientificTracks Abstracts: J Cancer Sci Ther

DOI: 10.4172/1948-5956.C1.081

Abstract
The newest version of NCCN guidelines (1.2016) and recently published American Society of Clinical Oncology Clinical Practice Guideline on use of biomarkers to guide decisions on adjuvant systemic therapy for women with early stage invasive breast cancer give guidelines for use of multigene assays for breast cancer patients. Nation-wide data on current clinical practice across the United States regarding utilization of multigene assays in clinical practice is lacking, as well as data on the impact of the assays on chemotherapy administration (ChemoA). Retrospective observational study of National Cancer Data Base (NCDB) patients from 2010-2012 was used to investigate utilization and impact of multigene assays in breast cancer patients across the United States. NCDB depicts ~70% of all newly diagnosed malignancies in the USA annually. De-identified data of patients that had multigene assay results were analyzed. 513,080 patients had BC; 406,525 were estrogen receptor-positive (ER+). 91,651 patients had OncotypeDX 21-gene assay, 2,518 had MammaPrint 70-gene assay, 2,321 had other (unspecified) multigene assay, and 1,020 had test performed but unknown type. Results addressing impact of race, socioeconomic status, geographic location and adherence to the guidelines applicable at the time of the study on utilization of multigene assays will be discussed as well as compliance with treatment recommendations based on the multigene assay test results.
Biography

Amila Orucevic obtained MD degree from Medical School of University of Sarajevo, Bosnia and Herzegovina (1983) and PhD from The University of Western Ontario, London, Ontario, Canada (1996). She is a board certified pathologist for Anatomic and Clinical Pathology by The American Board of Pathology (2002), and board certified pathologist for Anatomic Pathology by The Royal College of Physicians and Surgeons of Canada (2002). Currently she is attending/staff pathologist, Associate Professor and Director of Research at the Department of Pathology, The University of Tennessee Medical Center, Knoxville, TN, USA. She published 26 papers in peer reviewed journals.

Email: [email protected]

Relevant Topics
Top